Diagnosis and management of monoclonal gammopathy of clinical significance

The term “monoclonal gammopathy of clinical significance” (MGCS) refers to any plasma cell or B-cell clonal disorder that does not meet the current criteria for malignant disorders but produces a monoclonal protein that directly or indirectly results in organ damage. The most commonly affected organ...

Descripción completa

Detalles Bibliográficos
Autor principal: Cho, Hyungwoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057659/
https://www.ncbi.nlm.nih.gov/pubmed/35483921
http://dx.doi.org/10.5045/br.2022.2022035
_version_ 1784697948017262592
author Cho, Hyungwoo
author_facet Cho, Hyungwoo
author_sort Cho, Hyungwoo
collection PubMed
description The term “monoclonal gammopathy of clinical significance” (MGCS) refers to any plasma cell or B-cell clonal disorder that does not meet the current criteria for malignant disorders but produces a monoclonal protein that directly or indirectly results in organ damage. The most commonly affected organs are the kidneys, nerves, and skin. This review summarizes the current classification of MGCS and its diagnostic and treatment approaches.
format Online
Article
Text
id pubmed-9057659
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
record_format MEDLINE/PubMed
spelling pubmed-90576592022-05-10 Diagnosis and management of monoclonal gammopathy of clinical significance Cho, Hyungwoo Blood Res Review Article The term “monoclonal gammopathy of clinical significance” (MGCS) refers to any plasma cell or B-cell clonal disorder that does not meet the current criteria for malignant disorders but produces a monoclonal protein that directly or indirectly results in organ damage. The most commonly affected organs are the kidneys, nerves, and skin. This review summarizes the current classification of MGCS and its diagnostic and treatment approaches. Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2022-04-30 2022-04-30 /pmc/articles/PMC9057659/ /pubmed/35483921 http://dx.doi.org/10.5045/br.2022.2022035 Text en © 2022 Korean Society of Hematology https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Cho, Hyungwoo
Diagnosis and management of monoclonal gammopathy of clinical significance
title Diagnosis and management of monoclonal gammopathy of clinical significance
title_full Diagnosis and management of monoclonal gammopathy of clinical significance
title_fullStr Diagnosis and management of monoclonal gammopathy of clinical significance
title_full_unstemmed Diagnosis and management of monoclonal gammopathy of clinical significance
title_short Diagnosis and management of monoclonal gammopathy of clinical significance
title_sort diagnosis and management of monoclonal gammopathy of clinical significance
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057659/
https://www.ncbi.nlm.nih.gov/pubmed/35483921
http://dx.doi.org/10.5045/br.2022.2022035
work_keys_str_mv AT chohyungwoo diagnosisandmanagementofmonoclonalgammopathyofclinicalsignificance

Ejemplares similares